Hospital-based evidence on cost-effectiveness of brucellosis diagnostic tests and treatment in Kenyan hospitals
Hospitals in Kenya continue to use the Febrile Antigen Brucella Agglutination Test (FBAT) to diagnose brucellosis, despite reports showing its inadequacy. This study generated hospital-based evidence on the performance and cost-effectiveness of the FBAT, compared to the Rose Bengal Test (RBT).Twelve...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Journal Article |
| Lenguaje: | Inglés |
| Publicado: |
Public Library of Science
2021
|
| Materias: | |
| Acceso en línea: | https://hdl.handle.net/10568/110774 |
| _version_ | 1855541061038899200 |
|---|---|
| author | Alumasa, Lorren Thomas, Lian F. Amanya, Fredrick Njoroge, Samuel M. Moriyón, I. Makhandia, Josiah Rushton, Jonathan Fèvre, Eric M. Falzon, Laura C. |
| author_browse | Alumasa, Lorren Amanya, Fredrick Falzon, Laura C. Fèvre, Eric M. Makhandia, Josiah Moriyón, I. Njoroge, Samuel M. Rushton, Jonathan Thomas, Lian F. |
| author_facet | Alumasa, Lorren Thomas, Lian F. Amanya, Fredrick Njoroge, Samuel M. Moriyón, I. Makhandia, Josiah Rushton, Jonathan Fèvre, Eric M. Falzon, Laura C. |
| author_sort | Alumasa, Lorren |
| collection | Repository of Agricultural Research Outputs (CGSpace) |
| description | Hospitals in Kenya continue to use the Febrile Antigen Brucella Agglutination Test (FBAT) to diagnose brucellosis, despite reports showing its inadequacy. This study generated hospital-based evidence on the performance and cost-effectiveness of the FBAT, compared to the Rose Bengal Test (RBT).Twelve hospitals in western Kenya stored patient serum samples that were tested for brucellosis using the FBAT, and these were later re-tested using the RBT. Data on the running time and cost of the FBAT, and the treatment prescribed for brucellosis, were collected. The cost-effectiveness of the two tests, defined as the cost in US Dollars ($) per Disability Adjusted Life Year (DALY) averted, was determined, and a basic sensitivity analysis was run to identify the most influential parameters. Over a 6-month period, 180 patient serum samples that were tested with FBAT at the hospitals were later re-tested with RBT at the field laboratory. Of these 24 (13.3%) and 3 (1.7%) tested positive with FBAT and RBT, respectively. The agreement between the FBAT and RBT was slight (Kappa = 0.12). Treatment prescribed following FBAT positivity varied between hospitals, and only one hospital prescribed a standardized therapy regimen. The mean $/DALY averted when using the FBAT and RBT were $2,065 (95% CI $481-$6,736) and $304 (95% CI $126-$604), respectively. Brucellosis prevalence was the most influential parameter in the cost-effectiveness of both tests. Extrapolation to the national level suggested that an estimated $338,891 (95% CI $47,000-$1,149,000) per year is currently spent unnecessarily treating those falsely testing positive by FBAT. These findings highlight the potential for misdiagnosis using the FBAT. Furthermore, the RBT is cost-effective, and could be considered as the mainstay screening test for human brucellosis in this setting. Lastly, the treatment regimens must be harmonized to ensure the appropriate use of antibiotics for treatment. |
| format | Journal Article |
| id | CGSpace110774 |
| institution | CGIAR Consortium |
| language | Inglés |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | Public Library of Science |
| publisherStr | Public Library of Science |
| record_format | dspace |
| spelling | CGSpace1107742025-12-08T10:11:39Z Hospital-based evidence on cost-effectiveness of brucellosis diagnostic tests and treatment in Kenyan hospitals Alumasa, Lorren Thomas, Lian F. Amanya, Fredrick Njoroge, Samuel M. Moriyón, I. Makhandia, Josiah Rushton, Jonathan Fèvre, Eric M. Falzon, Laura C. brucellosis diagnosis zoonoses health Hospitals in Kenya continue to use the Febrile Antigen Brucella Agglutination Test (FBAT) to diagnose brucellosis, despite reports showing its inadequacy. This study generated hospital-based evidence on the performance and cost-effectiveness of the FBAT, compared to the Rose Bengal Test (RBT).Twelve hospitals in western Kenya stored patient serum samples that were tested for brucellosis using the FBAT, and these were later re-tested using the RBT. Data on the running time and cost of the FBAT, and the treatment prescribed for brucellosis, were collected. The cost-effectiveness of the two tests, defined as the cost in US Dollars ($) per Disability Adjusted Life Year (DALY) averted, was determined, and a basic sensitivity analysis was run to identify the most influential parameters. Over a 6-month period, 180 patient serum samples that were tested with FBAT at the hospitals were later re-tested with RBT at the field laboratory. Of these 24 (13.3%) and 3 (1.7%) tested positive with FBAT and RBT, respectively. The agreement between the FBAT and RBT was slight (Kappa = 0.12). Treatment prescribed following FBAT positivity varied between hospitals, and only one hospital prescribed a standardized therapy regimen. The mean $/DALY averted when using the FBAT and RBT were $2,065 (95% CI $481-$6,736) and $304 (95% CI $126-$604), respectively. Brucellosis prevalence was the most influential parameter in the cost-effectiveness of both tests. Extrapolation to the national level suggested that an estimated $338,891 (95% CI $47,000-$1,149,000) per year is currently spent unnecessarily treating those falsely testing positive by FBAT. These findings highlight the potential for misdiagnosis using the FBAT. Furthermore, the RBT is cost-effective, and could be considered as the mainstay screening test for human brucellosis in this setting. Lastly, the treatment regimens must be harmonized to ensure the appropriate use of antibiotics for treatment. 2021-01-07 2021-01-09T16:07:16Z 2021-01-09T16:07:16Z Journal Article https://hdl.handle.net/10568/110774 en Open Access Public Library of Science Alumasa, L., Thomas, L.F., Amanya, F., Njoroge, S.M., Moriyón, I., Makhandia, J., Rushton, J., Fèvre, E.M. and Falzon, L.C. 2021. Hospital-based evidence on cost-effectiveness of brucellosis diagnostic tests and treatment in Kenyan hospitals. PLOS Neglected Tropical Diseases 15(1): e0008977. |
| spellingShingle | brucellosis diagnosis zoonoses health Alumasa, Lorren Thomas, Lian F. Amanya, Fredrick Njoroge, Samuel M. Moriyón, I. Makhandia, Josiah Rushton, Jonathan Fèvre, Eric M. Falzon, Laura C. Hospital-based evidence on cost-effectiveness of brucellosis diagnostic tests and treatment in Kenyan hospitals |
| title | Hospital-based evidence on cost-effectiveness of brucellosis diagnostic tests and treatment in Kenyan hospitals |
| title_full | Hospital-based evidence on cost-effectiveness of brucellosis diagnostic tests and treatment in Kenyan hospitals |
| title_fullStr | Hospital-based evidence on cost-effectiveness of brucellosis diagnostic tests and treatment in Kenyan hospitals |
| title_full_unstemmed | Hospital-based evidence on cost-effectiveness of brucellosis diagnostic tests and treatment in Kenyan hospitals |
| title_short | Hospital-based evidence on cost-effectiveness of brucellosis diagnostic tests and treatment in Kenyan hospitals |
| title_sort | hospital based evidence on cost effectiveness of brucellosis diagnostic tests and treatment in kenyan hospitals |
| topic | brucellosis diagnosis zoonoses health |
| url | https://hdl.handle.net/10568/110774 |
| work_keys_str_mv | AT alumasalorren hospitalbasedevidenceoncosteffectivenessofbrucellosisdiagnostictestsandtreatmentinkenyanhospitals AT thomaslianf hospitalbasedevidenceoncosteffectivenessofbrucellosisdiagnostictestsandtreatmentinkenyanhospitals AT amanyafredrick hospitalbasedevidenceoncosteffectivenessofbrucellosisdiagnostictestsandtreatmentinkenyanhospitals AT njorogesamuelm hospitalbasedevidenceoncosteffectivenessofbrucellosisdiagnostictestsandtreatmentinkenyanhospitals AT moriyoni hospitalbasedevidenceoncosteffectivenessofbrucellosisdiagnostictestsandtreatmentinkenyanhospitals AT makhandiajosiah hospitalbasedevidenceoncosteffectivenessofbrucellosisdiagnostictestsandtreatmentinkenyanhospitals AT rushtonjonathan hospitalbasedevidenceoncosteffectivenessofbrucellosisdiagnostictestsandtreatmentinkenyanhospitals AT fevreericm hospitalbasedevidenceoncosteffectivenessofbrucellosisdiagnostictestsandtreatmentinkenyanhospitals AT falzonlaurac hospitalbasedevidenceoncosteffectivenessofbrucellosisdiagnostictestsandtreatmentinkenyanhospitals |